Published in Rev Med Interne on December 21, 2004
Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol (2000) 4.89
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34
HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J (1999) 2.16
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther (2014) 2.11
Caspase activation is required for terminal erythroid differentiation. J Exp Med (2001) 1.97
Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med (2008) 1.93
Drugs that may injure the respiratory system. Eur Respir J (1997) 1.86
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia (2013) 1.65
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother (1994) 1.64
Developmental changes in human megakaryopoiesis. J Thromb Haemost (2013) 1.63
Brief report: heavy-chain deposition disease. N Engl J Med (1993) 1.63
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem (1999) 1.60
Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol (1995) 1.43
Heart involvement in Churg-Strauss syndrome: retrospective study in French Burgundy population in past 10 years. Eur J Intern Med (2010) 1.40
[Association of celiac disease and antiphospholipid syndrome]. Presse Med (1998) 1.39
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst (1997) 1.38
Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood (1999) 1.38
Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res (2001) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest (1994) 1.34
In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int J Cancer (1994) 1.33
Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res (1998) 1.25
HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res (1997) 1.22
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia (2013) 1.22
JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene (2011) 1.21
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia (2013) 1.21
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother (1993) 1.21
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol (2007) 1.20
The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. J Virol (2000) 1.18
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res (1997) 1.16
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Mitochondria in hematopoiesis and hematological diseases. Oncogene (2006) 1.11
Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol (2000) 1.11
Human FOXP3 and cancer. Oncogene (2010) 1.10
Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene (2001) 1.09
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (1995) 1.07
Prophylactic fluconazole and Candida krusei infection. N Engl J Med (1992) 1.07
Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem (2011) 1.06
Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene (2000) 1.05
Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ (2008) 1.05
Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J (1996) 1.05
Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J (1998) 1.03
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Br J Cancer (2003) 1.03
An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia (2013) 1.03
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med (2011) 1.02
Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ (1998) 1.02
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) (2008) 1.01
Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene (2001) 1.00
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol (2000) 0.99
Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene (1998) 0.98
Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J Biochem (1996) 0.98
Asbestos, ergot drugs and the pleura. Eur Respir J (1997) 0.98
Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood (2001) 0.98
Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol (2001) 0.97
Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene (1999) 0.96
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ (2010) 0.95
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis (2012) 0.94
Concurrent lymphoma and metastatic breast carcinoma in the axillary, confounding sentinel lymph-node biopsy. Eur J Surg Oncol (2004) 0.94
Caspase-2, a novel lipid sensor under the control of sterol regulatory element binding protein 2. Mol Cell Biol (2005) 0.94
Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene (2010) 0.94
False aneurysm of the internal carotid artery in Behçet's disease: successful combined endovascular treatment with stent and coils. Rheumatology (Oxford) (1999) 0.93
[Evaluation of balance in neurologic and geriatric disorders]. Ann Readapt Med Phys (2005) 0.93
Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene (2006) 0.93
Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res (1986) 0.93
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood (2001) 0.92
Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res (1990) 0.92
Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol (2005) 0.90
p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene (1999) 0.90
Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. J Biol Chem (2001) 0.89
Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell Death Differ (2005) 0.89
Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors. Int J Cancer (1999) 0.89
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer (2010) 0.88
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer (1992) 0.88
A role of HSPs in apoptosis through "protein triage"? Cell Death Differ (2003) 0.88
Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res (1993) 0.87
Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene (2001) 0.87
Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Res (2000) 0.87
Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int J Cancer (1995) 0.87
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]. Cancer Radiother (2011) 0.86
Comparison of motor strategies in sit-to-stand and back-to-sit motions between healthy and Alzheimer's disease elderly subjects. Neuroscience (2005) 0.86
Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol (1984) 0.86
The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene (2010) 0.86
STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun (1999) 0.86
[The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats]. Chirurgie (1999) 0.86
Bone marrow necrosis and human parvovirus associated infection preceding an Ph1+ acute lymphoblastic leukemia. Leuk Lymphoma (1992) 0.86
Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis (1992) 0.85
Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate-buffered hemodialysis. Arch Intern Med (1984) 0.85
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol (2011) 0.85
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia (2012) 0.85
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J (2015) 0.85